{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:49:31Z","timestamp":1791575371256,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T00:00:00Z","timestamp":1526860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic>The majority of adverse drug reactions (ADRs) reported in the summary of product characteristics (SPCs) are based on pivotal clinical trials, performed under controlled conditions and with selected patients.<jats:italic>Objectives<\/jats:italic>(1) to observe ADRs in the real-world setting and to evaluate if the supervision of the pharmacist impacts on the management of ADRs and on the satisfaction of patients; (2) to sensitise health professionals and patients on the need to increase the reporting of ADRs, in compliance with Pharmacovigilance.<jats:italic>Setting<\/jats:italic>CRO Aviano, Italian National Cancer Institute.<jats:italic>Method<\/jats:italic>From February 2013 to April 2015, we conducted an observational study enrolling 154 patients (\u2265\u200918\u00a0years) undergoing treatment with at least one of ten targeted-therapies included in the study.<jats:italic>Main outcome<\/jats:italic>ADR\u00a0reporting in the\u00a0real-world setting. Patient satisfaction with clinical pharmacist support.<jats:italic>Results<\/jats:italic>Reported ADRs in the real setting do not always correspond with\u00a0data described in the respective SPCs. Unknown ADRs were also identified such as hyperglycaemia with lenalidomide and sorafenib; and hypomagnesaemia with bevacizumab. We also observed a 124.3% increase in spontaneous reports.<jats:italic>Conclusion<\/jats:italic>This study shows the high value of active pharmacovigilance programs, and our results might be a starting point for developing a randomised trial which should aim to demonstrate the impact of the pharmacist on improving patient\u2019s adherence and in measuring the difference in ADRs reports in the different arms followed or not by the pharmacist.<\/jats:p>","DOI":"10.1007\/s11096-018-0653-5","type":"journal-article","created":{"date-parts":[[2018,5,21]],"date-time":"2018-05-21T03:42:43Z","timestamp":1526874163000},"page":"795-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance"],"prefix":"10.1007","volume":"40","author":[{"given":"G.","family":"Fornasier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Taborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Francescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Polesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"De Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-7120","authenticated-orcid":false,"given":"P.","family":"Baldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"issue":"1","key":"653_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1570163812666150602144310","volume":"12","author":"TA Baudino","year":"2015","unstructured":"Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12(1):13\u201320.","journal-title":"Curr Drug Discov Technol"},{"issue":"2","key":"653_CR2","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1200\/JCO.2010.31.9624","volume":"29","author":"B Seruga","year":"2011","unstructured":"Seruga B, Sterling L, Wang L, Tannok IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol. 2011;29(2):174\u201385.","journal-title":"J Clin Oncol"},{"key":"653_CR3","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","volume":"169","author":"JP Ioannidis","year":"2009","unstructured":"Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Arch Intern Med. 2009;169:1737\u20139.","journal-title":"Arch Intern Med"},{"key":"653_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2710.2007.00815.x","volume":"2","author":"KC Sokol","year":"2007","unstructured":"Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;2:169\u201375.","journal-title":"J Clin Pharm Ther"},{"key":"653_CR5","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551\u20135.","journal-title":"Br J Cancer"},{"key":"653_CR6","unstructured":"European Medicines Agency (EMA). Pharmacovigilance. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000258.jsp. Accessed 19 Feb 2018."},{"issue":"25","key":"653_CR7","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1200\/JCO.2015.61.7613","volume":"33","author":"P Baldo","year":"2015","unstructured":"Baldo P, Fornasier G, Francescon S, Ferrarin E, Truccolo I, De Paoli P. Toxicities and adverse drug reactions experienced during anticancer treatment: it is desirable to consider the problem within the international system of pharmacovigilance. J Clin Oncol. 2015;33(25):2824\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"653_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/17512433.2015.974555","volume":"8","author":"M Tuccori","year":"2015","unstructured":"Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli R, Fornai M, et al. Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2015;8(1):61\u201375.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10","key":"653_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/BF03261977","volume":"35","author":"J Inch","year":"2012","unstructured":"Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review. Drug Saf. 2012;35(10):807\u201318.","journal-title":"Drug Saf"},{"issue":"4","key":"653_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40264-013-0026-x","volume":"36","author":"E Basch","year":"2013","unstructured":"Basch E. Systematic collection of patient-reported adverse drug reactions: a path to patient-centred pharmacovigilance. Drug Saf. 2013;36(4):277\u20138.","journal-title":"Drug Saf"},{"key":"653_CR11","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). http:\/\/www.meddra.org. Accessed 08 Feb 2017."},{"key":"653_CR12","unstructured":"The Uppsala Monitoring Center: the use of the WHO-UMC system for standardised case causality assessment. https:\/\/www.who-umc.org\/media\/2768\/standardised-case-causality-assessment.pdf. Accessed 14 Aug 2017."},{"key":"653_CR13","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Avastin. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000582\/WC500029271.pdf. Accessed 14 Aug 2017."},{"key":"653_CR14","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Afinitor. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001038\/WC500022814.pdf. Accessed 14 Aug 2017."},{"key":"653_CR15","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Erbitux. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000558\/WC500029119.pdf. Accessed 14 Aug 2017."},{"key":"653_CR16","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Glivec. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000406\/WC500022207.pdf. Accessed 14 Aug 2017."},{"key":"653_CR17","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Nexavar. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000690\/WC500027704.pdf. Accessed 14 Aug 2017."},{"key":"653_CR18","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Revlimid. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf. Accessed 14 Aug 2017."},{"key":"653_CR19","unstructured":"European Medicines Agency (EMA). Summary of Product Characteristics (SPC). Sutent. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000687\/WC500057737.pdf. Accessed 14 Aug 2017."},{"key":"653_CR20","unstructured":"Agenzia Italiana del Farmaco (AIFA). Rete Nazionale di Farmacovigilanza. https:\/\/www.agenziafarmaco.gov.it\/Farmacovigilanza\/. Accessed 14 Aug 2017."},{"key":"653_CR21","unstructured":"EudraVigilance. ADR report. http:\/\/www.adrreports.eu\/en\/search.html. Accessed 14 Aug 2017."},{"key":"653_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000366226","volume":"88","author":"P Barth\u00e9l\u00e9my","year":"2015","unstructured":"Barth\u00e9l\u00e9my P, Asmane-De la Porte I, Meyer N, Duclos B, Serra S, Dourthe LM, Am\u00e9 S, Litique V, Giron C, Goldbarg V, Fornecker L, Quoix E, Kurtz JE. Adherence and patients\u2019 attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies. Oncology. 2015;88:1\u20138.","journal-title":"Oncology."},{"issue":"11","key":"653_CR23","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(16)30312-6","volume":"17","author":"PJ Pitts","year":"2016","unstructured":"Pitts PJ, Louet HL, Moride Y, Conte RM. 21st century pharmacovigilance: efforts, roles, and responsibilities. Lancet Oncol. 2016;17(11):e486\u201392.","journal-title":"Lancet Oncol"},{"key":"653_CR24","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","volume":"33","author":"M Di Maio","year":"2015","unstructured":"Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33:910\u20135.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"653_CR25","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.3747\/co.v17is1.615","volume":"17","author":"M Fakih","year":"2010","unstructured":"Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 2010;17(Suppl 1):S18\u201330.","journal-title":"Curr Oncol."},{"issue":"6","key":"653_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1517\/14740338.2016.1167186","volume":"15","author":"MD Berger","year":"2016","unstructured":"Berger MD, Lenz HJ. The safety of monoclonal antibodies for treatment of colorectal cancer. Expert Opin Drug Saf. 2016;15(6):799\u2013808.","journal-title":"Expert Opin Drug Saf"},{"key":"653_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","author":"WY Lam","year":"2015","unstructured":"Lam WY, Fresco P. Medication adherence measure: an overview. BioMed Res Int. 2015. https:\/\/doi.org\/10.1155\/2015\/217047.","journal-title":"BioMed Res Int"},{"issue":"10","key":"653_CR28","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s40264-016-0441-x","volume":"39","author":"L H\u00e4rmark","year":"2016","unstructured":"H\u00e4rmark L, Raine J, Leufkens H, Edwards IR, Moretti U, Sarinic VM, et al. Patient-reported safety information: a renaissance of pharmacovigilance? Drug Saf. 2016;39(10):883\u201390.","journal-title":"Drug Saf"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-0653-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-0653-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:58:30Z","timestamp":1751648310000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-0653-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["653"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-0653-5","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"25 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}